The first trail results showed that VB-111 was safe and specific and may offer additive effect to chemotherapy.
In the trial, the researchers investigated the safety and efficacy of VB-111 as monotherapy, in combination with bevacizumab and in combination with carboplatin and pemetrexed in a Lewis Lung metastasis model and found that VB-111 induced a dose-dependent tumor reduction of up to 90%.
However, in the second study, VB-111 stands as a promising candidate as a treatment for glioblastoma.
The second trial examined the impact of VB-111 on tumor growth in rats with established intracranial xenografts.
The results demonstrated decreased tumor size in animals treated with VB-111, with those rats showing a median survival of 48 days, versus 38 days for untreated rats.